TY - JOUR
TI - Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target
AU - Zeidan, B.
AU - Jackson, T.R.
AU - Larkin, S.E.T.
AU - Cutress, R.I.
AU - Coulton, G.R.
AU - Ashton-Key, M.
AU - Murray, N.
AU - Packham, G.
AU - Gorgoulis, V.
AU - Garbis, S.D.
AU - Townsend, P.A.
JO - OncoTargets and therapy
PY - 2015
VL - 6
TODO - 25
SP - 21421-21427
PB - Impact Journals, LLC
SN - null
TODO - 10.18632/oncotarget.4070
TODO - glycerophosphoinositol inositolphosphodiesterase;  conditioned medium;  glycerophosphoinositol inositolphosphodiesterase;  tumor marker, Article;  breast cancer;  breast carcinoma;  breast disease;  cancer cell;  cell migration;  controlled study;  diagnostic value;  enzyme linked immunosorbent assay;  human;  human cell;  human tissue;  immunohistochemistry;  in vitro study;  major clinical study;  mass spectrometry;  protein blood level;  protein expression;  upregulation;  aged;  breast;  breast tumor;  cell motion;  conditioned medium;  epithelium;  female;  gene expression regulation;  gene silencing;  matrix-assisted laser desorption-ionization mass spectrometry;  MCF-7 cell line;  metabolism;  metastasis;  middle aged;  pathology;  proteomics;  tumor cell line;  tumor invasion, Aged;  Annexin A3;  Biomarkers, Tumor;  Breast;  Breast Neoplasms;  Cell Line, Tumor;  Cell Movement;  Culture Media, Conditioned;  Enzyme-Linked Immunosorbent Assay;  Epithelium;  Female;  Gene Expression Regulation, Neoplastic;  Gene Silencing;  Humans;  Immunohistochemistry;  Mass Spectrometry;  MCF-7 Cells;  Middle Aged;  Neoplasm Invasiveness;  Neoplasm Metastasis;  Proteomics;  Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
TODO - Breast cancers are the most common cancer-affecting women; critically the identification of novel biomarkers for improving early detection, stratification and differentiation from benign tumours is important for the reduction of morbidity and mortality. To identify and functionally characterise potential biomarkers, we used mass spectrometry (MS) to analyse serum samples representing control, benign breast disease (BBD) and invasive breast cancer (IDC) patients. Complementary and multidimensional proteomic approaches were used to identify and validate novel serum markers. Annexin A3 (ANX A3) was found to be differentially expressed amongst different breast pathologies. The diagnostic value of serum ANX A3 was subsequently validated by ELISA in an independent serum set representing the three groups. Here, ANX A3 was significantly upregulated in the benign disease group sera compared with other groups (P < 0.0005). In addition, paired breast tissue immunostaining confirmed that ANX A3 was abundantly expressed in benign and to a lesser extent malignant neoplastic epithelium. Finally, we illustrated ANX A3 expression in cell culture lysates and conditioned media from neoplastic breast cell lines, and its role in neoplastic breast cell migration in vitro. This study confirms the novel role of ANX A3 as a mammary biomarker, regulator and therapeutic target.
ER -